Want to see AU:CYP full AI Analyst Report?
Cynata Therapeutics Limited (CYP) AI Stock Analysis
Cynata Therapeutics Limited
(ASX:CYP)
The score is driven primarily by severe financial weakness, including ongoing losses, cash burn, and a fragile capital position. Weak long-term technical momentum and negative earnings-based valuation provide little support, although the absence of debt and the stock’s relatively low momentum readings are modest mitigating factors.
Cynata Therapeutics Limited (CYP) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 1.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 650.74K
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 1.00
- Revenue Growth
- ―
- EPS Growth
- 13.67%
- Country
- Australia
- Employees
- 0
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cynata Therapeutics Limited Business Overview & Revenue Model
Company Description
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem...
Cynata Therapeutics Limited Financial Statement Overview
Summary
Severe financial weakness: persistent losses, negative operating and free cash flow, declining assets and equity, and negative shareholders’ equity in the latest period. No debt is a mitigating strength, but the supplied financial statement scores indicate substantial funding and execution risk.
Income Statement
30NegativeBalance Sheet
18Very NegativeCash Flow
24Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 1.71M | 1.89M | 2.32M | 1.65M | 7.77M |
| Gross Profit | -260.31K | -260.31K | 1.89M | 2.32M | 1.37M | 7.49M |
| EBITDA | -9.43M | -9.42M | -9.33M | -9.95M | -15.65M | -6.00M |
| Net Income | -9.25M | -9.25M | -9.39M | -9.74M | -14.28M | -5.45M |
Balance Sheet | ||||||
| Total Assets | 1.35M | 1.35M | 7.20M | 8.39M | 18.99M | 26.55M |
| Cash, Cash Equivalents and Short-Term Investments | 897.42K | 897.42K | 5.05M | 6.21M | 16.17M | 23.80M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.75M | 1.75M | 1.22M | 1.17M | 2.26M | 2.59M |
| Stockholders Equity | -394.24K | -394.24K | 5.98M | 7.22M | 16.73M | 23.96M |
Cash Flow | ||||||
| Free Cash Flow | -6.74M | -6.74M | -8.77M | -9.96M | -14.28M | -3.30M |
| Operating Cash Flow | -6.74M | -6.74M | -8.72M | -9.96M | -14.28M | -3.30M |
| Investing Cash Flow | 0 | 0 | -50.00K | 0 | 0 | 0 |
| Financing Cash Flow | 2.58M | 2.58M | 7.61M | 0 | 6.72M | 210.12K |
Cynata Therapeutics Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CYP, the sentiment is Neutral. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and below the 200-day MA of 0.16, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 60.45 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:CYP.
Cynata Therapeutics Limited Peers Comparison
Overall Rating
AU:MSB64Neutral
AU:OCC50Neutral
AU:CMB41Neutral
AU:1AI40Underperform- AU:CYP39Underperform
AU:TRP32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:MSB | 64Neutral | AUD 2.94B | -35.83 | -10.06% | ― | 555.67% | 49.08% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:OCC | 50Neutral | AUD 149.82M | -10.38 | -36.83% | ― | 51.07% | -47.63% |
| AU:CMB | 41Neutral | AUD 11.77M | -1.59 | -247.44% | ― | -4.24% | 33.39% |
| AU:1AI | 40Underperform | AUD 20.28M | -5.71 | -132.20% | ― | ― | -200.00% |
| AU:CYP | 39Underperform | AUD 4.02M | -0.31 | -617.89% | ― | ― | 13.67% |
| AU:TRP | 32Underperform | AUD 5.06M | -1.07 | -52.04% | ― | 32.22% | -26.53% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:CYP | Cynata Therapeutics Limited | 0.01 | -0.22 | -94.78% | |
| AU:1AI | Living Cell Technologies Ltd. | 0.01 | 0.00 | 0.00% | |
| AU:MSB | Mesoblast Limited | 2.26 | -0.22 | -8.87% | |
| AU:OCC | Orthocell Ltd | 0.55 | -0.64 | -53.78% | |
| AU:TRP | Tissue Repair Ltd | 0.10 | -0.24 | -71.21% | |
| AU:CMB | Regeneus Ltd. | 0.40 | -0.09 | -19.19% |
Cynata Therapeutics Limited Corporate Events
Cynata Director Paul Wotton to Exit Board as Company Enters New Strategic Phase
Cynata Therapeutics has announced that Non-Executive Director Dr Paul Wotton will step down from the board following the company’s Annual General Meeting on 25 November 2026. Wotton, who joined in 2016 and served as chair from 2017 to 2020, pla...
Cynata Offers Fee-Free Exit for Small Shareholders via Unmarketable Parcel Facility
Cynata Therapeutics has launched a share sale facility for holders of unmarketable parcels, defined as shareholdings worth less than A$500, to allow small investors to exit their positions without brokerage or handling costs. At the record date, thes...
Cynata Sets Target Market for New Share Options in Revised Prospectus
Cynata Therapeutics Limited has issued a new target market determination for options to acquire fully paid ordinary shares, linked to a revised transaction-specific prospectus dated 12 October 2026. The document replaces an earlier determination and...
Cynata Launches Fully Underwritten Entitlement Offer via Replacement Prospectus
Cynata Therapeutics Limited has issued a replacement prospectus for a renounceable pro rata entitlement offer to existing shareholders. Eligible investors are invited to subscribe for three new shares for every eight held, at $0.01 per share, with on...
Cynata defines target market for new options in capital raising
Cynata Therapeutics has issued a target market determination for new options over its ordinary shares, linked to a 3-for-8 pro rata renounceable entitlement offer and associated shortfall and underwriting arrangements. The options, which are unquoted...
Cynata Therapeutics Launches Renounceable Entitlement Offer to Raise Capital
Cynata Therapeutics has launched a non-accelerated, renounceable pro rata entitlement offer, allowing eligible shareholders to subscribe for 3 new shares for every 8 held at $0.01 per share, with one free attaching option for every 3 new shares, to r...
Cynata Plans Issue of 18 Million Options to Support Capital Needs
Cynata Therapeutics Limited has notified the ASX of a proposed issue of new securities in the form of options. The company plans to issue up to 18,000,000 options, exercisable at $0.02 and expiring on May 3, 2029, with a proposed issue date of Novemb...
Cynata Therapeutics Launches Major Renounceable Pro Rata Offer
Cynata Therapeutics has announced a renounceable pro rata offer to issue up to 91,295,388 new ordinary fully paid shares and 30,431,796 options exercisable at $0.02 and expiring on 3 May 2029. The offer, with key dates in October and an issue date of...
Cynata launches discounted entitlement offer to fund strategic review
Cynata Therapeutics has launched a fully underwritten, three-for-eight renounceable entitlement offer to raise about $913,000, with new shares priced at $0.01, a 9.1% discount to the prior ASX close, and accompanied by free attaching options exercisa...
Cynata Ends Equity Facility With Acuity, Plans Buyback of Security Shares
Cynata Therapeutics has moved to terminate its At-the-Market Subscription Deed with Acuity Capital, which had provided up to $7.5 million in standby equity capital, effective 14 October 2026. The company previously raised $1.204 million under this fa...
Cynata Uses $1.7m R&D Refund to Clear Loan and Bolster Cymerus Strategy
Cynata Therapeutics has received a Research and Development Tax Incentive refund of $1.694 million from the Australian Government for the 2025/2026 financial year, reflecting ongoing investment in its Cymerus mesenchymal stromal cell technology. The...
Cynata Extends R&D Tax Incentive Loan Ahead of $1.7m Rebate
Cynata Therapeutics Limited has secured an extension of the maturity date on its $600,000 Research and Development Tax Incentive loan facility from 30 September 2026 to 30 November 2026, under an agreement with its commercial lender. The facility is...
Cynata Updates Corporate Governance Framework to Strengthen Board Oversight
Cynata Therapeutics has released an updated Corporate Governance Statement outlining how its board manages and oversees the company in line with the ASX Corporate Governance Principles and Recommendations. The statement details a clear separation of...
Cynata Releases 2025/2026 Annual Report and Confirms Corporate Structure
Cynata Therapeutics Limited has released its annual report for the financial year ended 30 June 2026, outlining its corporate structure and governance arrangements. The report details the company’s registered office, board composition, auditors...
Cynata Adjusts 2026 Results After GvHD Trial Close-Out Accrual
Cynata Therapeutics has revised its audited financial results for the year ended 30 June 2026 following the completion of its audit, recognising an additional accrual related to its Phase 2 clinical trial of CYP-001 in acute graft-versus-host disease...
Cynata Options Lapse, Streamlining ASX-Listed Capital Structure
Cynata Therapeutics Limited has updated the market on changes to its capital structure following the expiry of several tranches of listed options. On 10 September 2026, a total of 3 million options with exercise prices ranging from $0.40 to $0.60 rea...
Cynata narrows loss but trial setbacks and cash squeeze deepen going-concern risk
Cynata Therapeutics reported a net loss of $9.1 million for the year to 30 June 2026, slightly improved from the prior year, as revenues fell and cash reserves dropped to $0.9 million. The group moved from net assets to net liabilities and recorded a...
Cynata Plans ASX-Quoted Share Placement to Raise Capital
Cynata Therapeutics Limited has notified the ASX of a proposed issue of up to 2,000,000 ordinary fully paid shares. The placement, scheduled for issue on 30 October 2026, is intended to be quoted on the ASX in line with listing rule requirements, sig...
Cynata Slashes Costs After Key Cell Therapy Trials Miss Efficacy Targets
Cynata Therapeutics reported June quarter results marked by disappointing efficacy outcomes in two key Cymerus-based cell therapy programs, despite acceptable safety profiles. The Phase 2 trial of CYP-001 in high-risk acute graft versus host disease...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 22, 2026